ALC News and Press, Alcon Inc. From 06/04/23

2023-06-04 12:00:08 ET Billions of dollars in sales across various MedTech markets will be at stake if there is a broader acceptance of weight loss drugs developed by Novo Nordisk ( NVO ) and Eli Lilly ( NYSE: LLY ), Morgan Stanley argued in a research note last week. Novo N...

CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company” Nasdaq: LFCR), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has entered into a broad set of ...

Alcon in Action, a company-wide community volunteerism initiative, reinforces the company’s year-round commitment to community engagement and bolsters Alcon’s aspiration to improve lives and strengthen communities Thousands of company associates across 30 countries participa...

2023-05-15 08:24:01 ET Summary Alcon has experienced consistent revenue growth in recent years, the stability of both the company and the industry doesn't warrant a compelling investment case at its current valuation multiples. The eye care industry is a worldwide market that may ...

2023-05-12 16:05:07 ET Summary National Vision Holdings has done well for itself in recent years, and that trend looks set to continue as the company opens more stores. This value-centric brand is quite healthy, and shares are reasonably priced, though not the cheapest. In all...

2023-05-10 13:30:04 ET Alcon Inc. (ALC) Q1 2023 Earnings Conference Call May 10, 2023, 08:00 AM ET Company Participants Dan Cravens - VP, IR David Endicott - CEO Tim Stonesifer - CFO Conference Call Participants Anthony Petrone - Mizuho Group Matt...

2023-05-10 08:10:14 ET Alcon Inc. ( NYSE: ALC ) added ~4% pre-market Wednesday as Baird upgraded it to Outperform from Neutral and raised it price target to $90 from $75 per share after the contact lens maker topped Street forecasts with its Q1 2023 financials. The analyst...

2023-05-09 16:32:49 ET Alcon press release ( NYSE: ALC ): Q1 Non-GAAP EPS of $0.70 beats by $0.09 . Revenue of $2.3B (+7% Y/Y) beats by $60M . Net sales of $9.2-$9.4B vs $9.28B consensus EPS of $2.55-$.265 vs $2.60 consensus For further details see: ...

First quarter 2023 sales of $2.3 billion, up 7%, or 11% constant currency (1) (cc) First quarter 2023 diluted EPS of $0.35, up 3%, or up 26% cc; core diluted EPS (2) of $0.70 up 3%, or 14% cc Dividend of CHF 0.21 per share approved by shareholders at the Annual General Mee...

An investigator led, non-interventional study evaluated the performance of two monofocal intraocular lenses (IOLs) in 620 eyes of 310 cataract patients in the U.S. 1 Clareon monofocal IOL provides excellent distance vision, and intermediate vision that is non-inferior to TECNIS Eyhanc...